PARP inhibitors in metastatic prostate cancer: Evidence to date

Emily Nizialek, Emmanuel S. Antonarakis

Research output: Contribution to journalReview articlepeer-review

55 Scopus citations


Poly (ADP-ribose) polymerase inhibitors (PARPi) are a unique class of antineoplas-tic agents that function by inducing synthetic lethality. Synthetic lethality occurs when PARPi and either another agent or an underlying genetic alteration together lead to overwhelming DNA damage and ultimately cell death. PARPi first showed promise as a cancer therapy in patients with BRCA1/2 mutations and have become part of standard treatment for breast and ovarian cancer. In prostate cancer, two PARPi, rucaparib and olaparib, have been FDA approved for the treatment of metastatic castration-resistant prostate cancer (mCRPC). While both agents are approved for tumors with BRCA1/2 alterations, for olaparib the indication is also expanded to patients with 12 other homologous recombination deficiency (HRD) gene alterations including ATM and PALB2. PARPi differ in their pharmacokinetics and pharmacodynamics, and additional studies are being conducted with niraparib, veliparib, and talazoparib in prostate cancer. While PARPi are fairly well tolerated, common toxicities include hematologic (anemia/thrombocyto-penia) and gastrointestinal effects (nausea/vomiting). Ongoing studies are being conducted combining PARPi with other agents in patients with and without HRD alterations. Early data are promising for the combination of PARPi with second-generation antiandrogens and with immunotherapy. As additional trials are developed and reported, the hope is that the patient population who may benefit from PARPi will continue to expand.

Original languageEnglish (US)
Pages (from-to)8105-8114
Number of pages10
JournalCancer Management and Research
StatePublished - 2020
Externally publishedYes

Bibliographical note

Funding Information:
Dr Antonarakis is partially funded by NIH grant P30 CA006973 and DOD grant W81XWH-16-PCRP-CCRSA.

Publisher Copyright:
© 2020 Nizialek and Antonarakis.


  • Homologous recombination
  • PARP inhibitor
  • Prostate cancer


Dive into the research topics of 'PARP inhibitors in metastatic prostate cancer: Evidence to date'. Together they form a unique fingerprint.

Cite this